Human papillomavirus vaccine introduction in low and middle income countries: guidance on the use of cost-effectiveness models Mark Jit1, Nadia Demarteau2†, Elamin Elbasha3†, Gary Ginsberg4†, Jane Kim5†, Naiyana Praditsitthikorn6†, Edina Sinanovic7† and Raymond Hutubessy8* † Contributed equally 8

Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand Naiyana Praditsitthikorn,1,2 Yot Teerawattananon,1,3 Sripen Tantivess,1,3 Supon Limwattananon,3 Arthorn Riewpaiboon,2 Saibua Chichareon,4 Nantakan Ieumwananonthachai5 and Viroj Tangcharoensathien3

Systematic Review of Economic Evaluations of Preparedness Strategies and Interventions against Influenza Pandemics. Roma´n Pe´ rez Velasco1*, Naiyana Praditsitthikorn1, Kamonthip Wichmann1, Adun Mohara1, Surachai Kotirum1, Sripen Tantivess1, Constanza Vallenas2, Hande Harmanci2, Yot Teerawattanan

Full text can be accessed from: http://www.sciencedirect.com/science/article/pii/S0264410X14017058

Benjarin Santatiwongchai1, Varit Chantarastapornchit1*, Thomas Wilkinson2, Kittiphong Thiboonboon1, Waranya Rattanavipapong1, Damian G Walker3, Kalipso Chalkidou2, Yot Teerawattananon1 1 Health Intervention and Technology Assessment Program, Nonthaburi, Thailand, 2 NICE International,National Insti

Veronika J Wirtz*, Hans V Hogerzeil*, Andrew L Gray*, Maryam Bigdeli, Cornelis P de Joncheere, Margaret A Ewen, Martha Gyansa-Lutterodt, Sun Jing, Vera L Luiza, Regina M Mbindyo, Helene Möller, Corrina Moucheraud, Bernard Pécoul, Lembit Rägo, Arash Rashidian, Dennis Ross-Degnan, Peter N Stephens,

Abstract Background The World Health Organization (WHO) has developed the Total System Effectiveness (TSE) framework to assist national policy-makers in prioritizing vaccines. The pilot was launched in Thailand to explore the potential use of TSE in a country with established governance struct

Beyond vaccine safety, efficacy and procurement lie licensing and delivery — nations must get ready. There are currently more than 40 candidate vaccines for COVID-19 in clinical evaluation, and more than 150 in preclinical development. Creating a safe and effective vaccine is akin to striking bas

Abstract Innovations in vaccine product attributes could play an important role in addressing coverage and equity (C&E) gaps, but there is currently a poor understanding of the full system impact and trade-offs associated with investing in such technologies, both from the perspective of natio